Objective To observe the clinical effect of intravitreal lucentis combined with compound anisodine hydrobromide and laser photocoagulation on the treatment of diabetic macular edema. Methods Sixty-eight patients (112eyes) who were diagnosed with diabetic macular edema by ocular-fundus examination and fundus fluorescein angiography (FFA) were chosen. Fifty of them were treated with only laser photocoagulation and others were treated with intraviatreal lucentis combined with compound anisodine hydrobromide and laser photocoagulation. Visual BCVA, CMT and postoperative complications were observed. Results Among patients with intravitreal lucentis combined compound anisodine hydrbromide ,the case of visual cure was 47 (83.9%), the case of visual improvement was 2 or more, no change is 6 (10.7) visual decrease is 3 patients (5.4%). Edema in 53 patients (86.8%) reduced after treatment. Among patients with laser phptocoagulation, the case of visual recovery in 13 (23.2%), 31 patients had no change (55,4%) , 12 patients (21.4%) had a visual decrease. Edema in 18 patients (32.1%) reduced after treatment. Conclusion The cure effect of intravitreal lucentis combined with compound anisodine hydrobromide and laser photocoagulation is better than those of only using laser photocoagulation.%目的：观察雷珠单抗( ranibizumab)玻璃体腔内注射联合复方樟柳碱颞浅动脉旁皮下注射联合黄斑格栅样光凝治疗糖尿病黄斑水肿的临床疗效。方法确诊为糖尿病黄斑水肿的患者68例112眼，其中单眼30例，双眼38例，随机分为两组：一组为单纯激光光凝治疗组（简称单纯光凝组）56眼，另一组先行雷珠单抗玻璃体腔内注射联合复方樟柳碱颞浅动旁皮下注射，再于注药1周后行黄斑格栅样光凝（简称联合组）56眼。观察两组治疗后最佳矫正视力( BCVA)，光学相干断层扫描( OCT)显示的黄斑中心凹厚度( CMT)及术后并发症等。结果联合治疗组视力提高47眼（83.9%），视力不变6眼（10.7%），视力下降3眼（5.4%）。水肿吸收53眼（94.6%），水肿未退3眼（5.4%）。单纯光凝治疗组视力提高13眼（23.2%），视力不变31眼（55.4%），视力下降12眼（21.4%）。水肿吸收18眼（32.1%），水肿未退38眼（67.9%）。结论雷珠单抗玻璃体腔内注射联合复方樟柳碱颞浅动脉旁皮下注射可促进黄斑囊水肿的吸收，提高患者视力，降低黄斑中心凹厚度，联合黄斑格栅样光凝治疗更能保证疗效稳定而持久。
展开▼
